Ligand, Royalty Pharma Expand SERM Royalty Agreement, Form New Royalty Partnership for Targretin Capsules

San Diego, CA, and New York, NY (BUSINESS WIRE) – January 6, 2003 – Ligand to use increased proceeds of up to $15.4 million through 2003 to accelerate development of Targretin Capsules in NSCLC monotherapy and Targretin Gel in hand dermatitis

Source: Original Article